Wnt deregulation in rhabdomyosarcoma
Editorial Commentary

Wnt deregulation in rhabdomyosarcoma

Abhinav Adhikari, Judith Davie

Department of Biochemistry and Molecular Biology, Southern Illinois University School of Medicine and Simmons Cancer Institute, Carbondale, IL, USA

Correspondence to: Judith Davie. Department of Biochemistry and Molecular Biology, Southern Illinois University School of Medicine and Simmons Cancer Institute, Carbondale, IL, USA. Email: jdavie@siumed.edu.

Comment on: Hayes MN, McCarthy K, Jin A, et al. Vangl2/RhoA Signaling Pathway Regulates Stem Cell Self-Renewal Programs and Growth in Rhabdomyosarcoma. Cell Stem Cell 2018;22:414-27.e6.


Received: 08 May 2019; Accepted: 06 June 2019; Published: 20 June 2019.

doi: 10.21037/sci.2019.06.03


Signaling pathways integrate extracellular cues into intracellular gene expression profiles. Cell proliferation and differentiation are governed by many different signaling pathways that relay the extracellular spatiotemporal signals into the appropriate pattern of gene regulation within cells. There is complex interconnection and cross-talk between the signaling pathways during the process of development and regeneration, including during skeletal muscle regeneration and development. Wnt signaling has been shown to play an essential role in the regulation of the myogenic regulatory factors (MRFs) during embryonic development and adult muscle regeneration (1-3). Any alteration in signaling pathway input can lead to diseased conditions, including cancer.

Given their essential role in governing cell fate, signaling pathways modulators are pharmacologically relevant targets for cancer and many other diseases. In cancer, a high incidence of relapse is largely attributed to cellular heterogeneity. Of the two common models postulated for such heterogeneity; mutation accumulation or stem cell populations losing the capacity to differentiate, the stem cell-like population hypothesis is particularly relevant for pediatric cancers, such as rhabdomyosarcoma. In pediatric cancers, the mutational burden is low because of the limited time cells have to accumulate cellular damage and the resulting DNA mutations. Therefore, identifying and understanding the biology of stem cell-like cell types is of utmost importance for clinical and therapeutic relevance. A recent manuscript by Hayes et al. in Cell Stem Cell describes the role of the van gogh-like 2 (VANGL2) protein in the regulation of self-renewal of tumor propagating cells (TPC), a stem cell like population, in rhabdomyosarcoma (4).

Rhabdomyosarcoma is a pediatric sarcoma that has two primary subtypes; embryonal (ERMS) and alveolar (ARMS). The Langenau group identified VANGL2 as a driver of TPCs by examining RNA sequencing results from primary rhabdomyosarcoma patient samples (5). This analysis identified several upregulated genes associated with the non-canonical Wnt/planar cell polarity (PCP) signaling pathway in both subtypes of RMS. This group included an essential regulator of Wnt/PCP signaling, VANGL2. VANGL2 proteins have well characterized roles in development and regeneration and display minimal cross talk with the Wnt/β-catenin signaling pathway (1,6).

TPCs are of major interest as these cells are responsible for continued tumor growth and relapse. TPCs share self-renewal properties with non-transformed stem cells (7). TPCs can undergo symmetrical cell divisions to produce identical daughter cells and thus expand the pool of cells capable of driving tumor growth, elevating metastasis and evading therapy. TPCs can also divide asymmetrically to maintain tumor producing cells while also producing more differentiated cells that have specialized functions necessary for supporting cancer progression and invasion.

Hayes et al. show that VANGL2 is highly expressed in both subtypes of RMS. This upregulation could be seen at the mRNA and protein level in human cell lines representing both ERMS and ARMS. VANGL2 mRNA upregulation was also seen in a majority of primary patient samples. However, the rarity of cells (<10%) positive for VANGL2 in primary samples indicated a functional heterogeneity in the cell types represented. VANGL2 depletion in human cell lines representing ARMS (RH30) and ERMS (RD) showed that VANGL2 was required for cell proliferation and morphology. The depletion of VANGL2 inhibited cell proliferation and decreased the percentage of cells in S phase. The expression of genes associated with progenitor like cells, such as PAX7, were down regulated and the expression of genes associated with differentiation, such as MYOD, were upregulated upon VANGL2 depletion. VANGL2 depletion reduced colony formation and induced differentiation in human RMS in vitro models. Xenograft assays were used to assess the role of VANGL2 in growth and differentiation of RMS in vivo and VANGL2 depleted cells showed decreases in tumor volume in both ERMS and ARMS. Excised tumors resulting from the VANGL2 depleted cells showed reductions in cellularity and fewer proliferative cells. Tumors showed no increase in cleaved caspase 3 expression, indicating that apoptosis was not active in these cells. Conversely, increases in skeletal muscle differentiation markers such as MYOD and MYOG were observed.

To gain additional insight into the role of VANGL2 within heterogeneous cell types in RMS, human cell lines representing ERMS (RD) and ARMS (RH30) were assessed by immunofluorescence. While only a fraction of RMS cells expressed VANGL2, this population was actively dividing, unlike cells with low levels of VANGL2, which appeared non mitotic. Interestingly, the majority of VANGL2+ cells showed a subcellular localization like what is seen during normal development in polarized, actively dividing satellite cells, the muscle stem cell precursors (8). VANGL2+ cells co-expressed a marker for progenitor cell fate, PAX7. VANGL2+ cells also expressed high levels of additional gene expression markers associated with progenitor like properties of RMS cells. These data led the Langenau group to propose that VANGl2 may both be a marker for TPCs and required for TPC renewal.

VANGL2 depletion was also found to strongly inhibit 3D rhabdosphere colony formation, an assay used to estimate self renewal, suggesting that VANGL2 was required for maintenance of human RMS TPCs. The role of VANGL2 in TPC maintenance was further supported using a zebrafish ERMS model. The Langenau group previously established a kRASG12D zebrafish model of ERMS that has been shown to share molecular and histopathological features with human RMS (9-11). Using this model, they showed that VANGL2 does not affect over all tumor formation, penetration or latency, suggesting that VANGL2 has minimal effects on tumor initiation. However, extreme limiting dilution analysis (ELDA) showed that VANGL2 expression increased the number of TPCs by 9-fold as detected by engraftment rates. A transgenic labeling strategy expressed mCherry under the control of the vangl2 promoter (vangl2:mCherry). This reporter showed that VANGL2 expression was correlated with robust engraftment and propagation of RMS. VANGL2 was also combined with the previously characterized myf5:GFP+ transgenic reporter (9). When transplanted at a limiting dilution, it was found that myf5:GFP+/vangl2:mCherry+ cells propagated ERMS with higher efficiency than myf5:GFP+ alone and led to a downregulation of muscle differentiation markers. In all transgenic studies, it was found that VANGL2 expression had to be correlated with less mature cell markers such as rag2:GFP+ or myf5:GFP+ to drive engraftment and propagation. More mature cells do not propagate ERMS, irrespective of the expression of VANGL2. Finally, the Langenau group showed that the RhoA protein acts downstream of VANGL2 to regulate the self-renewal and number of TPC cells. Together, the work shows the novel and essential role VANGL2 plays during TPC self-renewal and in establishing cell heterogeneity.

RhoA had been previously shown to regulate MYOD (12) and potentially ties the regulation of TPC proliferation and self-renewal with differentiation. We have shown that canonical Wnt signaling directly regulates the expression of MYOD through binding of β-catenin in the distal regulatory region (DRR) of the Myod promoter (13). The Langenau group has shown that MYF5 and MYOD are required for growth and self renewal in human RMS (14) and it will be important to further define the relationship between VANGL2/RhoA and the MYOD transcription family members in driving RMS tumor growth.

The role of both canonical and non-canonical Wnt signaling in the regulation of stem cell proliferation and differentiation has been extensively studied (15). The Wnt signaling pathway plays an essential role in the normal growth and regeneration of skeletal muscle and is required for skeletal muscle differentiation (2). Recently, the role of an epigenetic chromatin regulator, JARID2, was shown to regulate embryonic stem cell (ESC) proliferation and differentiation through modulation of the non-canonical Wnt signaling pathway and regulation of Nanog expression, which controls pluripotency and self-renewal in ESCs (16). The loss of JARID2 in ESCs resulted in constitutive expression of Nanog, reduced activity of β-catenin and impaired ESC differentiation. Our lab recently extended the role of JARID2 to normal skeletal muscle differentiation and showed that JARID2, in a PRC2 complex dependent manner, is required to initiate muscle differentiation via regulation of MYOD gene expression (13). We found that JARID2 is required to activate MYOD through modulation of the canonical Wnt signaling pathway by direct repression of the Wnt antagonist, SFRP1. JARID2 and the PRC2 complex have been shown to be overexpressed in RMS cells and are required for cancer cell viability and aggressiveness (17-19). However, Wnt/β-catenin signaling has been shown to be impaired in RMS cells (20). The role of chromatin modifiers like JARID2 and the PRC2 complex in regulation of both canonical and non-canonical Wnt signaling pathways remains to be explored, but it is likely that they contribute to the regulation of self-renewal and maintenance of TPC like cells in RMS. Hayes et al. makes a compelling case for future studies into the role and deregulation of Wnt signaling in rhabdomyosarcoma and additional cancers.

Our lab has focused extensively on the role of the T-box protein TBX2 to drive the proliferation and tumorigenicity of RMS cells (21,22). We have shown that TBX2 regulates cell proliferation through the direct repression of CDKN1A, CDKN2A, and PTEN. In lung, Wnt/β-catenin signaling is shown to be downstream of TBX2 and TBX3 proteins, which modulate Wnt signaling through the repression of the Wnt antagonists Frzb and Shisa3, respectively (23). In liver cancer, Wnt/β-catenin signaling is upstream of TBX3 and a critical mediator of β-catenin functions (24). These studies highlight the importance and interconnectedness of T-box proteins and Wnt signaling pathways in tumorigenesis across cell types. Recently, we have found that TBX3 represses TBX2 gene expression under the control of the PRC2 complex in RMS and skeletal muscle (25), connecting the role of the PRC2 complex in the regulation of Tbx proteins, Wnt signaling and stem cell self-renewal and differentiation. Could JARID2 and the PRC2 complex regulate the self-renewal and maintenance of TPC like cells in RMS? This and many additional questions remain to be explored in understanding the pathways that drive cancer growth and metastasis.

Understanding all aspects of cell growth and proliferation is essential for designing therapeutic strategies to effectively target cancer cells. The Langenau group’s important study reveals an unexpected role of the non-canonical Wnt pathway in governing TPC maintenance and proliferation. It remains to be explored how Wnt pathway deregulation connects with other known drivers of RMS proliferation (Figure 1). The discovery of the essential role of VANGL2 in promoting TPC growth and tumor initiation opens many new avenues of discovery in cancer and stem cell biology and offers new targets for therapeutic strategy design.

Figure 1 Schematic depicts the role of the Wnt signaling pathways in rhabdomyosarcoma (RMS). The box represents known RMS drivers.

Acknowledgments

Funding: We would like to acknowledge all authors from the Davie lab whose work has been cited in this review. The Davie lab is supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health under Award Number RAR068622. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.


Footnote

Conflicts of Interest: The authors have no conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.


References

  1. von Maltzahn J, Chang NC, Bentzinger CF, et al. Wnt signaling in myogenesis. Trends Cell Biol 2012;22:602-9. [Crossref] [PubMed]
  2. Brack AS, Conboy IM, Conboy MJ, et al. A temporal switch from notch to Wnt signaling in muscle stem cells is necessary for normal adult myogenesis. Cell Stem Cell 2008;2:50-9. [Crossref] [PubMed]
  3. Jones AE, Price FD, Le Grand F, et al. Wnt/beta-catenin controls follistatin signalling to regulate satellite cell myogenic potential. Skelet Muscle 2015;5:14. [Crossref] [PubMed]
  4. Hayes MN, McCarthy K, Jin A, et al. Vangl2/RhoA Signaling Pathway Regulates Stem Cell Self-Renewal Programs and Growth in Rhabdomyosarcoma. Cell Stem Cell 2018;22:414-27.e6. [Crossref] [PubMed]
  5. Shern JF, Chen L, Chmielecki J, et al. Comprehensive genomic analysis of rhabdomyosarcoma reveals a landscape of alterations affecting a common genetic axis in fusion-positive and fusion-negative tumors. Cancer Discov 2014;4:216-31. [Crossref] [PubMed]
  6. Seifert JR, Mlodzik M. Frizzled/PCP signalling: a conserved mechanism regulating cell polarity and directed motility. Nat Rev Genet 2007;8:126-38. [Crossref] [PubMed]
  7. Kreso A, Dick JE. Evolution of the cancer stem cell model. Cell Stem Cell 2014;14:275-91. [Crossref] [PubMed]
  8. Le Grand F, Jones AE, Seale V, et al. Wnt7a activates the planar cell polarity pathway to drive the symmetric expansion of satellite stem cells. Cell Stem Cell 2009;4:535-47. [Crossref] [PubMed]
  9. Ignatius MS, Chen E, Elpek NM, et al. In vivo imaging of tumor-propagating cells, regional tumor heterogeneity, and dynamic cell movements in embryonal rhabdomyosarcoma. Cancer Cell 2012;21:680-93. [Crossref] [PubMed]
  10. Langenau DM, Keefe MD, Storer NY, et al. Effects of RAS on the genesis of embryonal rhabdomyosarcoma. Genes Dev 2007;21:1382-95. [Crossref] [PubMed]
  11. Chen EY, Deran MT, Ignatius MS, et al. Glycogen synthase kinase 3 inhibitors induce the canonical WNT/beta-catenin pathway to suppress growth and self-renewal in embryonal rhabdomyosarcoma. Proc Natl Acad Sci U S A 2014;111:5349-54. [Crossref] [PubMed]
  12. Gopinath SD, Narumiya S, Dhawan J. The RhoA effector mDiaphanous regulates MyoD expression and cell cycle progression via SRF-dependent and SRF-independent pathways. J Cell Sci 2007;120:3086-98. [Crossref] [PubMed]
  13. Adhikari A, Davie J. JARID2 and the PRC2 complex regulate skeletal muscle differentiation through regulation of canonical Wnt signaling. Epigenetics Chromatin 2018;11:46. [Crossref] [PubMed]
  14. Tenente IM, Hayes MN, Ignatius MS, et al. Myogenic regulatory transcription factors regulate growth in rhabdomyosarcoma. Elife 2017;6. [Crossref] [PubMed]
  15. Clevers H, Loh KM, Nusse R. Stem cell signaling. An integral program for tissue renewal and regeneration: Wnt signaling and stem cell control. Science 2014;346:1248012. [Crossref] [PubMed]
  16. Landeira D, Bagci H, Malinowski AR, et al. Jarid2 Coordinates Nanog Expression and PCP/Wnt Signaling Required for Efficient ESC Differentiation and Early Embryo Development. Cell Rep 2015;12:573-86. [Crossref] [PubMed]
  17. Walters ZS, Villarejo-Balcells B, Olmos D, et al. JARID2 is a direct target of the PAX3-FOXO1 fusion protein and inhibits myogenic differentiation of rhabdomyosarcoma cells. Oncogene 2014;33:1148-57. [Crossref] [PubMed]
  18. Ciarapica R, Carcarino E, Adesso L, et al. Pharmacological inhibition of EZH2 as a promising differentiation therapy in embryonal RMS. BMC Cancer 2014;14:139. [Crossref] [PubMed]
  19. Ciarapica R, De Salvo M, Carcarino E, et al. The Polycomb group. (PcG) protein EZH2 supports the survival of PAX3-FOXO1 alveolar rhabdomyosarcoma by repressing FBXO32 (Atrogin1/MAFbx). Oncogene 2014;33:4173-84. [Crossref] [PubMed]
  20. Annavarapu SR, Cialfi S, Dominici C, et al. Characterization of Wnt/beta-catenin signaling in rhabdomyosarcoma. Lab Invest 2013;93:1090-9. [Crossref] [PubMed]
  21. Zhu B, Zhang M, Byrum SD, et al. TBX2 blocks myogenesis and promotes proliferation in rhabdomyosarcoma cells. Int J Cancer 2014;135:785-97. [Crossref] [PubMed]
  22. Zhu B, Zhang M, Williams EM, et al. TBX2 represses PTEN in rhabdomyosarcoma and skeletal muscle. Oncogene 2016;35:4212-24. [Crossref] [PubMed]
  23. Ludtke TH, Rudat C, Wojahn I, et al. Tbx2 and Tbx3 Act Downstream of Shh to Maintain Canonical Wnt Signaling during Branching Morphogenesis of the Murine Lung. Dev Cell 2016;39:239-53. [Crossref] [PubMed]
  24. Renard CA, Labalette C, Armengol C, et al. Tbx3 is a downstream target of the Wnt/beta-catenin pathway and a critical mediator of beta-catenin survival functions in liver cancer. Cancer Res 2007;67:901-10. [Crossref] [PubMed]
  25. Oh TJ, Adhikari A, Mohamad T, et al. TBX3 represses TBX2 under the control of the PRC2 complex in skeletal muscle and rhabdomyosarcoma. Oncogenesis 2019;8:27. [Crossref] [PubMed]
doi: 10.21037/sci.2019.06.03
Cite this article as: Adhikari A, Davie J. Wnt deregulation in rhabdomyosarcoma. Stem Cell Investig 2019;6:13.